These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
283 related articles for article (PubMed ID: 36967222)
1. Determinants of cognitive and brain resilience to tau pathology: a longitudinal analysis. Bocancea DI; Svenningsson AL; van Loenhoud AC; Groot C; Barkhof F; Strandberg O; Smith R; ; La Joie R; Rosen HJ; Pontecorvo MJ; Rabinovici GD; van der Flier WM; Hansson O; Ossenkoppele R Brain; 2023 Sep; 146(9):3719-3734. PubMed ID: 36967222 [TBL] [Abstract][Full Text] [Related]
2. Assessment of Demographic, Genetic, and Imaging Variables Associated With Brain Resilience and Cognitive Resilience to Pathological Tau in Patients With Alzheimer Disease. Ossenkoppele R; Lyoo CH; Jester-Broms J; Sudre CH; Cho H; Ryu YH; Choi JY; Smith R; Strandberg O; Palmqvist S; Kramer J; Boxer AL; Gorno-Tempini ML; Miller BL; La Joie R; Rabinovici GD; Hansson O JAMA Neurol; 2020 May; 77(5):632-642. PubMed ID: 32091549 [TBL] [Abstract][Full Text] [Related]
3. Biological mechanisms of resilience to tau pathology in Alzheimer's disease. Svenningsson AL; Bocancea DI; Stomrud E; van Loenhoud A; Barkhof F; Mattsson-Carlgren N; Palmqvist S; Hansson O; Ossenkoppele R Alzheimers Res Ther; 2024 Oct; 16(1):221. PubMed ID: 39396028 [TBL] [Abstract][Full Text] [Related]
4. Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease: A Head-to-Head Comparison Against Amyloid Positron Emission Tomography and Magnetic Resonance Imaging. Ossenkoppele R; Smith R; Mattsson-Carlgren N; Groot C; Leuzy A; Strandberg O; Palmqvist S; Olsson T; Jögi J; Stormrud E; Cho H; Ryu YH; Choi JY; Boxer AL; Gorno-Tempini ML; Miller BL; Soleimani-Meigooni D; Iaccarino L; La Joie R; Baker S; Borroni E; Klein G; Pontecorvo MJ; Devous MD; Jagust WJ; Lyoo CH; Rabinovici GD; Hansson O JAMA Neurol; 2021 Aug; 78(8):961-971. PubMed ID: 34180956 [TBL] [Abstract][Full Text] [Related]
5. Tau pathology as determinant of changes in atrophy and cerebral blood flow: a multi-modal longitudinal imaging study. Visser D; Verfaillie SCJ; Bosch I; Brouwer I; Tuncel H; Coomans EM; Rikken RM; Mastenbroek SE; Golla SSV; Barkhof F; van de Giessen E; van Berckel BNM; van der Flier WM; Ossenkoppele R Eur J Nucl Med Mol Imaging; 2023 Jul; 50(8):2409-2419. PubMed ID: 36976303 [TBL] [Abstract][Full Text] [Related]
6. Inferior temporal tau is associated with accelerated prospective cortical thinning in clinically normal older adults. Scott MR; Hampton OL; Buckley RF; Chhatwal JP; Hanseeuw BJ; Jacobs HI; Properzi MJ; Sanchez JS; Johnson KA; Sperling RA; Schultz AP Neuroimage; 2020 Oct; 220():116991. PubMed ID: 32512123 [TBL] [Abstract][Full Text] [Related]
7. The accumulation rate of tau aggregates is higher in females and younger amyloid-positive subjects. Smith R; Strandberg O; Mattsson-Carlgren N; Leuzy A; Palmqvist S; Pontecorvo MJ; Devous MD; Ossenkoppele R; Hansson O Brain; 2020 Dec; 143(12):3805-3815. PubMed ID: 33439987 [TBL] [Abstract][Full Text] [Related]
8. Microglial activation and tau burden predict cognitive decline in Alzheimer's disease. Malpetti M; Kievit RA; Passamonti L; Jones PS; Tsvetanov KA; Rittman T; Mak E; Nicastro N; Bevan-Jones WR; Su L; Hong YT; Fryer TD; Aigbirhio FI; O'Brien JT; Rowe JB Brain; 2020 May; 143(5):1588-1602. PubMed ID: 32380523 [TBL] [Abstract][Full Text] [Related]
9. Cortical hypometabolism reflects local atrophy and tau pathology in symptomatic Alzheimer's disease. Strom A; Iaccarino L; Edwards L; Lesman-Segev OH; Soleimani-Meigooni DN; Pham J; Baker SL; Landau SM; Jagust WJ; Miller BL; Rosen HJ; Gorno-Tempini ML; Rabinovici GD; La Joie R; Brain; 2022 Apr; 145(2):713-728. PubMed ID: 34373896 [TBL] [Abstract][Full Text] [Related]
10. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition. Pontecorvo MJ; Devous MD; Navitsky M; Lu M; Salloway S; Schaerf FW; Jennings D; Arora AK; McGeehan A; Lim NC; Xiong H; Joshi AD; Siderowf A; Mintun MA; Brain; 2017 Mar; 140(3):748-763. PubMed ID: 28077397 [TBL] [Abstract][Full Text] [Related]
11. A multicentre longitudinal study of flortaucipir (18F) in normal ageing, mild cognitive impairment and Alzheimer's disease dementia. Pontecorvo MJ; Devous MD; Kennedy I; Navitsky M; Lu M; Galante N; Salloway S; Doraiswamy PM; Southekal S; Arora AK; McGeehan A; Lim NC; Xiong H; Truocchio SP; Joshi AD; Shcherbinin S; Teske B; Fleisher AS; Mintun MA Brain; 2019 Jun; 142(6):1723-1735. PubMed ID: 31009046 [TBL] [Abstract][Full Text] [Related]
12. Greater tau load and reduced cortical thickness in APOE ε4-negative Alzheimer's disease: a cohort study. Mattsson N; Ossenkoppele R; Smith R; Strandberg O; Ohlsson T; Jögi J; Palmqvist S; Stomrud E; Hansson O Alzheimers Res Ther; 2018 Aug; 10(1):77. PubMed ID: 30086796 [TBL] [Abstract][Full Text] [Related]
13. Phospho-tau with subthreshold tau-PET predicts increased tau accumulation rates in amyloid-positive individuals. Groot C; Smith R; Stomrud E; Binette AP; Leuzy A; Wuestefeld A; Wisse LEM; Palmqvist S; Mattsson-Carlgren N; Janelidze S; Strandberg O; Ossenkoppele R; Hansson O Brain; 2023 Apr; 146(4):1580-1591. PubMed ID: 36084009 [TBL] [Abstract][Full Text] [Related]
14. Sex modifies APOE ε4 dose effect on brain tau deposition in cognitively impaired individuals. Yan S; Zheng C; Paranjpe MD; Li Y; Li W; Wang X; Benzinger TLS; Lu J; Zhou Y Brain; 2021 Nov; 144(10):3201-3211. PubMed ID: 33876815 [TBL] [Abstract][Full Text] [Related]
15. Plasma VEGFA and PGF impact longitudinal tau and cognition in preclinical Alzheimer's disease. Yang HS; Yau WW; Carlyle BC; Trombetta BA; Zhang C; Shirzadi Z; Schultz AP; Pruzin JJ; Fitzpatrick CD; Kirn DR; Rabin JS; Buckley RF; Hohman TJ; Rentz DM; Tanzi RE; Johnson KA; Sperling RA; Arnold SE; Chhatwal JP Brain; 2024 Jun; 147(6):2158-2168. PubMed ID: 38315899 [TBL] [Abstract][Full Text] [Related]
16. Amyloid, tau and metabolic PET correlates of cognition in early and late-onset Alzheimer's disease. Tanner JA; Iaccarino L; Edwards L; Asken BM; Gorno-Tempini ML; Kramer JH; Pham J; Perry DC; Possin K; Malpetti M; Mellinger T; Miller BL; Miller Z; Mundada NS; Rosen HJ; Soleimani-Meigooni DN; Strom A; La Joie R; Rabinovici GD Brain; 2022 Dec; 145(12):4489-4505. PubMed ID: 35762829 [TBL] [Abstract][Full Text] [Related]
19. 18F-Flortaucipir PET Associations with Cerebrospinal Fluid, Cognition, and Neuroimaging in Mild Cognitive Impairment due to Alzheimer's Disease. Okafor M; Nye JA; Shokouhi M; Shaw LM; Goldstein F; Hajjar I J Alzheimers Dis; 2020; 74(2):589-601. PubMed ID: 32065800 [TBL] [Abstract][Full Text] [Related]
20. The metabolic brain signature of cognitive resilience in the 80+: beyond Alzheimer pathologies. Arenaza-Urquijo EM; Przybelski SA; Lesnick TL; Graff-Radford J; Machulda MM; Knopman DS; Schwarz CG; Lowe VJ; Mielke MM; Petersen RC; Jack CR; Vemuri P Brain; 2019 Apr; 142(4):1134-1147. PubMed ID: 30851100 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]